These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 32389534)

  • 21. Atrial fibrillation and coronary artery disease: a review on the optimal use of oral anticoagulants.
    Bocchino PP; Angelini F; Toso E
    Rev Cardiovasc Med; 2021 Sep; 22(3):635-648. PubMed ID: 34565066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
    Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial.
    Verburg A; Bor WL; Küçük IT; Henriques JPS; Vink MA; Ruifrok WT; Plomp J; Heestermans TACM; Schotborgh CE; Vlaar PJ; Magro M; Rikken SAOF; van den Broek WWA; van Mieghem CAG; Cornelis K; Rosseel L; Dujardin KS; Vandeloo B; Vandendriessche T; Ferdinande B; van 't Hof AWJ; Tijssen JGP; Limbruno U; De Caterina R; Rubboli A; Angiolillo DJ; Adriaenssens T; Dewilde W; Ten Berg JM
    EuroIntervention; 2024 Jul; 20(14):e898-e904. PubMed ID: 39007830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in Antiplatelet and Anticoagulant Therapies for NSTE-ACS.
    Badjatiya A; Rao SV
    Curr Cardiol Rep; 2019 Jan; 21(1):3. PubMed ID: 30637536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis.
    Vitolo M; Javed S; Capodanno D; Rubboli A; Boriani G; Lip GYH
    Expert Rev Cardiovasc Ther; 2020 Sep; 18(9):587-600. PubMed ID: 32772746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).
    Gibson CM; Mehran R; Bode C; Halperin J; Verheugt F; Wildgoose P; van Eickels M; Lip GY; Cohen M; Husted S; Peterson E; Fox K
    Am Heart J; 2015 Apr; 169(4):472-8.e5. PubMed ID: 25819853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
    Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
    Ten Berg JM; de Veer A; Oldgren J; Steg PG; Zateyshchikov DA; Jansky P; Seung KB; Hohnloser SH; Lip GYH; Nordaby M; Kleine E; Bhatt DL; Cannon CP;
    JACC Cardiovasc Interv; 2019 Dec; 12(23):2331-2341. PubMed ID: 31806214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI.
    Costa F; Valgimigli M; Steg PG; Bhatt DL; Hohnloser SH; Ten Berg JM; Miede C; Nordaby M; Lip GYH; Oldgren J; Cannon CP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):216-226. PubMed ID: 33258897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombotic therapies in Canadian atrial fibrillation patients with concomitant coronary artery disease: Insights from the CONNECT AF + PCI-II program.
    Chow JK; Bagai A; Tan MK; Har BJ; Yip AMC; Paniagua M; Elbarouni B; Bainey KR; Paradis JM; Maranda R; Cantor WJ; Eisenberg MJ; Dery JP; Madan M; Cieza T; Matteau A; Roth S; Lavi S; Glanz A; Gao D; Tahiliani R; Welsh RC; Kim HH; Robinson SD; Daneault B; Chong AY; Le May MR; Ahooja V; Gregoire JC; Nadeau PL; Laksman Z; Heilbron B; Yung D; Minhas K; Bourgeois R; Overgaard CB; Bonakdar H; Logsetty G; Lavoie AJ; De LaRochelliere R; Mansour S; Spindler C; Yan AT; Goodman SG;
    J Cardiol; 2023 Aug; 82(2):153-161. PubMed ID: 36931433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
    Xanthopoulou I; Dragona VM; Davlouros P; Tsioufis C; Iliodromitis E; Alexopoulos D;
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):191-196. PubMed ID: 29679301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Park J; Jung JH; Choi EK; Lee SW; Kwon S; Lee SR; Kang J; Han KD; Park KW; Oh S; Lip GYH
    PLoS One; 2022; 17(2):e0264538. PubMed ID: 35213632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.
    Angiolillo DJ; Goodman SG; Bhatt DL; Eikelboom JW; Price MJ; Moliterno DJ; Cannon CP; Tanguay JF; Granger CB; Mauri L; Holmes DR; Gibson CM; Faxon DP
    Circulation; 2018 Jul; 138(5):527-536. PubMed ID: 30571525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
    Naito R; Miyauchi K; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
    JAMA Cardiol; 2022 Aug; 7(8):787-794. PubMed ID: 35704345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.
    Chi G; Yee MK; Kalayci A; Kerneis M; AlKhalfan F; Mehran R; Bode C; Halperin JL; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Peterson ED; Fox KAA; Gibson CM
    J Thromb Thrombolysis; 2018 Oct; 46(3):346-350. PubMed ID: 29943350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients.
    Galli M; Andreotti F; Porto I; Crea F
    Europace; 2020 Apr; 22(4):538-546. PubMed ID: 31942971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis of Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Kuno T; Ueyama H; Takagi H; Ando T; Numasawa Y; Briasoulis A; Fox J; Bangalore S
    Am J Cardiol; 2020 Feb; 125(4):521-527. PubMed ID: 31839147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antithrombotic Treatment after Carotid Stenting in Patients with Concomitant Atrial Fibrillation.
    Pardo-Galiana B; Medina-Rodriguez M; Millan-Vazquez M; Cabezas-Rodriguez JA; Lebrato-Hernandez L; Ainz-Gomez L; Zapata-Arriaza E; Ortega J; de Albóniga-Chindurza A; Montaner J; Gonzalez A; Moniche F
    AJNR Am J Neuroradiol; 2022 May; 43(5):727-730. PubMed ID: 35393364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Triska J; Haddadin F; Madanat L; Jabri A; Daher M; Birnbaum Y; Jneid H
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):605-619. PubMed ID: 35829979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.